Date: 23 October 2018
Time: 6:30pm – 9:00pm PDT
ASU California Center – 725 Arizona Ave, Santa Monica, CA 90401
For decades the physical effects of chronic, life-threatening and terminal illnesses like cancer, MS and epilepsy have been treated with pharmaceutical drugs. However, the side effects of many pharmaceutical products used to manage pain have a significant negative impact for many users. The legalization of medical cannabis have not been legally available to patients worldwide.
Medicinal Cannabis is one of the hottest emerging sectors attracting early stage investors hoping to capitalize on the potential growth and high returns. The $2.757 billion in legal California marijuana sales are expected to grow more than 18 % annually to hit $5.6 billion by 2020.
Our distinguished panel will discuss the growth of this market in the U.S. to support startups with ambitious goals to deliver medically compliant cannabis products and manage the global demand.
The Panel will:
- Cover key topics in building a cannabis-related business in the U.S.
- Challenges and opportunities in the current investment environment, and
- What it will take for founders and entrepreneurs to establish their start-ups as an attractive investment.
Please join us on October 23rd for an informative, interactive session and networking.
Harry Nelson – Nelson Hardiman, LLP
Harry Nelson, co-chairman of the Adaptive Health Capital board and member of the investment committee, is a leading healthcare advisor best known for the eponymous law firm he founded, Nelson Hardiman, LLP.
Daniel Yi – MedMen
Daniel Yi is senior vice president of corporate communications and investor relations for MedMen Enterprises, the nation’s preeminent cannabis company and the most recognized brand in the emerging marijuana industry.
Dr. Nicco Reggente, PhD – WoahStork and Strain Genie
Dr. Reggente is a neuroscientist and entrepreneur with a passion for building technology that bridges the gap between the scientific community and the public. He is particularly interested in leveraging machine learning to foster a personalized medicine approach within the cannabis industry.